

## Special Issue

# Research of Anti-tumor Immune Responses to Gastrointestinal (GI) Cancers

### Message from the Guest Editor

New treatments such as immune checkpoint inhibitor, molecular-targeted agent, and antibody drug conjugate, developed for GI cancer, result in improving patient's outcome in the last decade. We believe that deep insight into the tumor immunological background of GI cancer will develop novel combination immunotherapy. Moreover, analyzing molecular background by gene panel testing using next-generation sequencer and then appropriate patient's selection are essential for the development of combination immunotherapy. Based on tumor immunology, Special Issue will highlight recent important and promising research for making breakthrough in immunotherapy for GI cancer.

### Guest Editor

Dr. Naoyuki Sakamoto

1. Department of Gastroenterology and Hepatology, Asahi University Hospital, Gifu 500-8523, Japan
2. Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan

### Deadline for manuscript submissions

closed (31 July 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/189298](https://mdpi.com/si/189298)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)